AIRLINK 173.79 Increased By ▲ 3.22 (1.89%)
BOP 11.36 Increased By ▲ 0.18 (1.61%)
CNERGY 8.64 Increased By ▲ 0.23 (2.73%)
CPHL 101.64 Increased By ▲ 1.91 (1.92%)
FCCL 46.94 Increased By ▲ 0.34 (0.73%)
FFL 15.39 Increased By ▲ 0.24 (1.58%)
FLYNG 27.79 Increased By ▲ 0.24 (0.87%)
HUBC 143.75 Increased By ▲ 5.97 (4.33%)
HUMNL 12.99 Increased By ▲ 0.07 (0.54%)
KEL 4.52 Decreased By ▼ -0.02 (-0.44%)
KOSM 5.76 Increased By ▲ 0.40 (7.46%)
MLCF 62.33 Decreased By ▼ -0.07 (-0.11%)
OGDC 212.02 Decreased By ▼ -0.14 (-0.07%)
PACE 5.47 Increased By ▲ 0.05 (0.92%)
PAEL 47.07 Decreased By ▼ -0.11 (-0.23%)
PIAHCLA 18.08 Decreased By ▼ -0.40 (-2.16%)
PIBTL 10.86 Increased By ▲ 0.50 (4.83%)
POWER 12.26 Decreased By ▼ -0.07 (-0.57%)
PPL 171.28 Increased By ▲ 1.68 (0.99%)
PRL 35.88 Increased By ▲ 0.03 (0.08%)
PTC 23.36 Increased By ▲ 0.27 (1.17%)
SEARL 96.96 Increased By ▲ 0.70 (0.73%)
SSGC 41.71 Increased By ▲ 2.19 (5.54%)
SYM 14.15 Increased By ▲ 0.31 (2.24%)
TELE 7.10 Decreased By ▼ -0.05 (-0.7%)
TPLP 9.96 Decreased By ▼ -0.07 (-0.7%)
TRG 63.89 Increased By ▲ 0.41 (0.65%)
WAVESAPP 10.02 Increased By ▲ 0.03 (0.3%)
WTL 1.33 Increased By ▲ 0.02 (1.53%)
YOUW 3.72 Increased By ▲ 0.06 (1.64%)
BR100 12,447 Increased By 142.3 (1.16%)
BR30 37,919 Increased By 504.1 (1.35%)
KSE100 116,390 Increased By 1536.7 (1.34%)
KSE30 35,696 Increased By 479.1 (1.36%)

The U.S. Food and Drug Administration said on Tuesday it has sent warning letters to four companies for selling unapproved versions of GLP-1 drugs including semaglutide and tirzepatide, the active ingredients in popular diabetes and weight-loss drugs.

The letters were issued to Xcel Peptides, Swisschems, Summit Research and Prime Peptides last week after the U.S. health regulator conducted a review of their respective websites in October.

The websites indicate that their products are labeled as “research use only” or “not for human consumption or clinical use.” However, evidence gathered by the FDA establishes that these products are actually intended to be used as drugs for humans.

The agency also sent a warning letter to Veronvy, which offers unapproved and misbranded oral GLP-1 products, including one that claims to be approved by the FDA.

The FDA has observed that the website offers misbranded products that misleadingly suggest that the drug products are approved or endorsed by the agency in some way.

Reckitt’s Mead Johnson Nutrition recalls baby formula powder from US: FDA

The companies must inform the agency within 15 business days of receiving the letter, outlining the specific actions taken to address any violations. Failure to adequately address the violations may result in legal action including, without limitation, seizure and injunction, the FDA said.

Semaglutide is an active ingredient in Novo Nordisk’s, Wegovy and Ozempic, while Eli Lilly’s,diabetes drug sold as Mounjaro and weight-loss drug Zepbound use the ingredient tirzepatide.

Some of the websites were also offering retatrutide, Eli Lilly’s experimental next generation weight-loss drug.

The companies have previously sued various medical spas, compounding facilities and clinics for selling products purporting to contain the active ingredients.

Comments

200 characters